Deubiquitinating enzymes as promising drug targets for infectious diseases

Current Pharmaceutical Design

Volumn 19, Issue 18, 2013, Pages 3234-3247

  Nanduri, Bindu ^a,b   Suvarnapunya, Akamol E ^c   Venkatesan, Malabi ^c   Edelmann, Mariola J ^a,b  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Deubiquitinating enzymes; Drug discovery; Infectious diseases; Post translational modifications; Ubiquitin

Indexed keywords

BETA INTERFERON; BORTEZOMIB; CEZANNE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DEUBIQUITINATING ENZYME; DEUBIQUITINATING ENZYME A; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; LATENCY ASSOCIATED NUCLEAR ANTIGEN; LATENCY ASSOCIATED NUCLEAR ANTIGEN 1; LDN 57444; LIGASE; OCTAMER TRANSCRIPTION FACTOR 1; RECOMBINANT ENZYME; RETINOIC ACID INDUCIBLE PROTEIN I; SHORT HAIRPIN RNA; TATA BINDING PROTEIN ASSOCIATED FACTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEASE 43; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN; WP 1130;

ANTIGEN PRESENTATION; ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; ATTENUATION; BACTERIAL STRAIN; CRYPTOCOCCUS NEOFORMANS; DENGUE VIRUS; DEUBIQUINATION; DRUG DESIGN; DRUG TARGETING; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE SILENCING; HEPATITIS B VIRUS; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE RESPONSE; IMMUNITY; INFECTION; INFLAMMATION; INFLUENZA VIRUS A; MEDIATOR; NONHUMAN; PLASMODIUM; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SUMOYLATION; TRICHINELLA SPIRALIS; UBIQUITINATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; COMMUNICABLE DISEASES; DRUG DESIGN; ENDOPEPTIDASES; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITIN; UBIQUITINATION; VIRAL PROTEINS;

EID: 84878887655     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319180008     Document Type: Review

References (140)

1. Alksne LE. Virulence as a target for antimicrobial chemotherapy. Expert Opin Investig Drugs 2002; 11: 1149-59.
2. Kerscher O, Felberbaum R, Hochstrasser M. Modification ofproteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006; 22: 159-80.
3. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-likeproteins as multifunctional signals. Nat Rev Mol Cell Biol 2005; 6: 599-609.
4. Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic andfunctional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-86.
5. Sun SC. Deubiquitylation and regulation of the immune response. Nat Rev Immunol 2008; 8: 501-11.
6. Edelmann MJ, Kessler BM. Ubiquitin and ubiquitin-like specificproteases targeted by infectious pathogens: Emerging patterns and molecular principles. Biochim Biophys Acta 2008; 1782: 809-16.
7. Eldridge AG, O'Brien T. Therapeutic strategies within the ubiquitinproteasome system. Cell Death Differ 2010; 17: 4-13.
8. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C. Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 2012; 31: 2373-88.
9. Kramer HB, Nicholson B, Kessler BM, Altun M. Detection ofubiquitin-proteasome enzymatic activities in cells: Application of activity-based probes to inhibitor development. Biochim Biophys Acta 2012.
10. Mattern MR, Wu J, Nicholson B. Ubiquitin-based anticancertherapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochim Biophys Acta 2012.
11. Harhaj EW, Dixit VM. Regulation of NF-kappaB bydeubiquitinases. Immunol Rev 2012; 246: 107-24.
12. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumoursuppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424: 801-5.
13. Jono H, Lim JH, Chen LF, et al. NF-kappaB is essential forinduction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 2004; 279: 36171-4.
14. Liu S, Lv J, Han L, et al. A pro-inflammatory role ofdeubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells. Biochem Biophys Res Commun 2012; 420: 78-83.
15. Yoshida H, Jono H, Kai H, Li JD. The tumor suppressorcylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280: 41111-21.
16. Espinosa L, Cathelin S, D'Altri T, et al. The Notch/Hes1 pathwaysustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 2010; 18: 268-81.
17. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CYLD is adeubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003; 424: 793-6.
18. Ahmed N, Zeng M, Sinha I, et al. The E3 ligase Itch anddeubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol 2011; 12: 1176-83.
19. Tsagaratou A, Kontoyiannis DL, Mosialos G. Truncation of thedeubiquitinating domain of CYLD in myelomonocytic cells attenuates inflammatory responses. Plos One 2011; 6: e16397.
20. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination andubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694-9.
21. Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper ininflammation and immunity. J Biol Chem 2009; 284: 8217-21.
22. Shembade N, Parvatiyar K, Harhaj NS, Harhaj EW. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J 2009; 28: 513-22.
23. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaBsignaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327: 1135-9.
24. Kayagaki N, Phung Q, Chan S, et al. DUBA: a deubiquitinase thatregulates type I interferon production. Science 2007; 318: 1628-32.
25. Gonzalez-Navajas JM, Law J, Nguyen KP, et al. Interleukin 1receptor signaling regulates DUBA expression and facilitates Toll like receptor 9-driven antiinflammatory cytokine production. J Exp Med 2010; 207: 2799-807.
26. Zhou F, Zhang X, van Dam H, et al. Ubiquitin-specific Protease 4Mitigates Toll-like/Interleukin-1 Receptor Signaling and Regulates Innate Immune Activation. J Biol Chem 2012; 287: 11002-10.
27. Colonne PM, Sahni A, Sahni SK. Rickettsia conorii infectionstimulates the expression of ISG15 and ISG15 protease UBP43 in human microvascular endothelial cells. Biochem Biophys Res Commun 2011; 416: 153-8.
28. Kim JH, Luo JK, Zhang DE. The level of hepatitis B virusreplication is not affected by protein ISG15 modification but is reduced by inhibition of UBP43 (USP18) expression. J Immunol 2008; 181: 6467-72.
29. Zou W, Kim JH, Handidu A, et al. Microarray analysis reveals thatType I interferon strongly increases the expression of immuneresponse related genes in Ubp43 (Usp18) deficient macrophages. Biochem Biophys Res Commun 2007; 356: 193-9.
30. Van Nguyen T, Angkasekwinai P, Dou H, et al. SUMO-specificprotease 1 is critical for early lymphoid development through regulation of STAT5 activation. Mol Cell 2012; 45: 210-21.
31. Ran Y, Liu TT, Zhou Q, et al. SENP2 negatively regulates cellularantiviral response by deSUMOylating IRF3 and conditioning it for ubiquitination and degradation. J Mol Cell Biol 2011; 3: 283-92.
32. Lee MH, Mabb AM, Gill GB, Yeh ET, Miyamoto S. NF-kappaBinduction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell 2011; 43: 180-91.
33. McCool KW, Miyamoto S. DNA damage-dependent NF-kappaBactivation: NEMO turns nuclear signaling inside out. Immunol Rev 2012; 246: 311-26.
34. Enesa K, Zakkar M, Chaudhury H, et al. NF-kappaB suppressionby the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem 2008; 283: 7036-45.
35. Maelfait J, Roose K, Bogaert P, et al. A20 (Tnfaip3) deficiency inmyeloid cells protects against influenza A virus infection. PLoS Pathog 2012; 8: e1002570.
36. Liao TL, Wu CY, Su WC, Jeng KS, Lai MM. Ubiquitination anddeubiquitination of NP protein regulates influenza A virus RNA replication. EMBO J 2010; 29: 3879-90.
37. Doukas T, Sarnow P. Escape from transcriptional shutoff duringpoliovirus infection: NF-kappaB-responsive genes IkappaBa and A20. J Virol 2011; 85: 10101-8.
38. Xu D, Lillico SG, Barnett MW, et al. USP18 restricts PRRSVgrowth through alteration of nuclear translocation of NF-kappaB p65 and p50 in MARC-145 cells. Virus Res 2012.
39. Lee BH, Lee MJ, Park S, et al. Enhancement of proteasomeactivity by a small-molecule inhibitor of USP14. Nature 2010; 467: 179-84.
40. Nag DK, Finley D. A small-molecule inhibitor of deubiquitinatingenzyme USP14 inhibits Dengue virus replication. Virus Res 2012; 165: 103-6.
41. Antrobus R, Boutell C. Identification of a novel higher molecularweight isoform of USP7/HAUSP that interacts with the Herpes simplex virus type-1 immediate early protein ICP0. Virus Res 2008; 137: 64-71.
42. Daubeuf S, Singh D, Tan Y, et al. HSV ICP0 recruits USP7 tomodulate TLR-mediated innate response. Blood 2009; 113: 3264-75.
43. Jager W, Santag S, Weidner-Glunde M, et al. The ubiquitin-specific protease USP7 modulates the replication of Kaposi's sarcoma-associated herpesvirus latent episomal DNA. J Virol 2012; 86: 6745-57.
44. Holowaty MN, Sheng Y, Nguyen T, Arrowsmith C, Frappier L. Protein interaction domains of the ubiquitin-specific protease,USP7/HAUSP. Journal of Biological Chemistry 2003; 278: 47753-47761.
45. Holowaty MN, Zeghouf M, Wu H, et al. Protein profiling withEpstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. J Biol Chem 2003; 278: 29987-94.
46. Sarkari F, Sanchez-Alcaraz T, Wang S, et al. EBNA1-mediatedrecruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication. PLoS Pathog 2009; 5: e1000624.
47. Lin CH, Chang HS, Yu WC. USP11 stabilizes HPV-16E7 andfurther modulates the E7 biological activity. J Biol Chem 2008; 283: 15681-8.
48. Vos RM, Altreuter J, White EA, Howley PM. The ubiquitin-specific peptidase USP15 regulates human papillomavirus type 16 E6 protein stability. J Virol 2009; 83: 8885-92.
49. Lavorgna A, Harhaj EW. An RNA interference screen identifiesthe Deubiquitinase STAMBPL1 as a critical regulator of human T-cell leukemia virus type 1 tax nuclear export and NF-kappaB activation. J Virol 2012; 86: 3357-69.
50. Yasunaga J, Lin FC, Lu X, Jeang KT. Ubiquitin-specific peptidase20 targets TRAF6 and human T cell leukemia virus type 1 tax to negatively regulate NF-kappaB signaling. J Virol 2011; 85: 6212-9.
51. Chen R, Zhang L, Zhong B, et al. The ubiquitin-specific protease17 is involved in virus-triggered type I IFN signaling. Cell Res 2010; 20: 802-11.
52. Li S, Zheng H, Mao AP, et al. Regulation of virus-triggeredsignaling by OTUB1-and OTUB2-mediated deubiquitination of TRAF3 and TRAF6. J Biol Chem 2010; 285: 4291-7.
53. Bottcher S, Maresch C, Granzow H, et al. Mutagenesis of theactive-site cysteine in the ubiquitin-specific protease contained in large tegument protein pUL36 of pseudorabies virus impairs viral replication in vitro and neuroinvasion in vivo. J Virol 2008; 82: 6009-16.
54. Kattenhorn LM, Korbel GA, Kessler BM, Spooner E, Ploegh HL.A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family Herpesviridae. Mol Cell 2005; 19: 547-57.
55. Bolstad M, Abaitua F, Crump CM, O'Hare P. Autocatalytic activityof the ubiquitin-specific protease domain of herpes simplex virus 1 VP1-2. J Virol 2011; 85: 8738-51.
56. Kim ET, Oh SE, Lee YO, Gibson W, Ahn JH. Cleavage specificityof the UL48 deubiquitinating protease activity of human cytomegalovirus and the growth of an active-site mutant virus in cultured cells. J Virol 2009; 83: 12046-56.
57. Saha A, Murakami M, Kumar P, et al. Epstein-Barr virus nuclearantigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 2009; 83: 4652-69.
58. Sompallae R, Gastaldello S, Hildebrand S, et al. Epstein-barr virusencodes three bona fide ubiquitin-specific proteases. J Virol 2008; 82: 10477-86.
59. Whitehurst CB, Ning S, Bentz GL, et al. The Epstein-Barr virus(EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity. J Virol 2009; 83: 4345-53.
60. Whitehurst CB, Vaziri C, Shackelford J, Pagano JS. Epstein-BarrVirus BPLF1 Deubiquitinates PCNA and Attenuates Polymerase eta Recruitment to DNA Damage Sites. J Virol 2012; 86: 8097-106.
61. Gastaldello S, Callegari S, Coppotelli G, et al. Herpes virusdeneddylases interrupt the cullin-RING ligase neddylation cycle by inhibiting the binding of CAND1. J Mol Cell Biol 2012; 4: 242-51.
62. Gastaldello S, Hildebrand S, Faridani O, et al. A deneddylaseencoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases. Nat Cell Biol 2010; 12: 351-61.
63. Jiang J, Tang H. Mechanism of inhibiting type I interferoninduction by hepatitis B virus X protein. Protein Cell 2010; 1: 1106-17.
64. Gonzalez CM, Wang L, Damania B. Kaposi's sarcoma-associatedherpesvirus encodes a viral deubiquitinase. J Virol 2009; 83: 10224-33.
65. Inn KS, Lee SH, Rathbun JY, et al. Inhibition of RIG-I-mediatedsignaling by Kaposi's sarcoma-associated herpesvirus-encoded deubiquitinase ORF64. J Virol 2011; 85: 10899-904.
66. Gredmark-Russ S, Isaacson MK, Kattenhorn L, et al. Agammaherpesvirus ubiquitin-specific protease is involved in the establishment of murine gammaherpesvirus 68 infection. J Virol 2009; 83: 10644-52.
67. Li SW, Lai CC, Ping JF, et al. Severe acute respiratory syndromecoronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways. J Gen Virol 2011; 92: 1127-40.
68. Zheng D, Chen G, Guo B, Cheng G, Tang H. PLP2, a potentdeubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res 2008; 18: 1105-13.
69. Clementz MA, Chen Z, Banach BS, et al. Deubiquitinating andinterferon antagonism activities of coronavirus papain-like proteases. J Virol 2010; 84: 4619-29.
70. Sun L, Xing Y, Chen X, et al. Coronavirus papain-like proteasesnegatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PLoS One 2012; 7: e30802.
71. Wang D, Fang L, Li P, et al. The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitinase. J Virol 2011; 85: 3758-66.
72. van Kasteren PB, Beugeling C, Ninaber DK, et al. Arterivirus andnairovirus ovarian tumor domain-containing Deubiquitinases target activated RIG-I to control innate immune signaling. J Virol 2012; 86: 773-85.
73. James TW, Frias-Staheli N, Bacik JP, et al. Structural basis for theremoval of ubiquitin and interferon-stimulated gene 15 by a viral ovarian tumor domain-containing protease. Proc Natl Acad Sci U S A 2011; 108: 2222-7.
74. Karpe YA, Lole KS. Deubiquitination activity associated withhepatitis E virus putative papain-like cysteine protease. J Gen Virol 2011; 92: 2088-92.
75. Li H, Zheng Z, Zhou P, et al. The cysteine protease domain ofporcine reproductive and respiratory syndrome virus non-structural protein 2 antagonizes interferon regulatory factor 3 activation. J Gen Virol 2010; 91: 2947-58.
76. Sun Z, Li Y, Ransburgh R, Snijder EJ, Fang Y. Nonstructuralprotein 2 of porcine reproductive and respiratory syndrome virus inhibits the antiviral function of interferon-stimulated gene 15. J Virol 2012; 86: 3839-50.
77. Holzer B, Bakshi S, Bridgen A, Baron MD. Inhibition of interferoninduction and action by the nairovirus Nairobi sheep disease virus/Ganjam virus. PLoS One 2011; 6: e28594.
78. Edelmann MJ, Kramer HB, Altun M, Kessler BM. Post-translational modification of the deubiquitinating enzyme otubain 1 modulates active RhoA levels and susceptibility to Yersinia invasion. FEBS J 2010; 277: 2515-30.
79. Juris SJ, Shah K, Shokat K, Dixon JE, Vacratsis PO. Identificationof otubain 1 as a novel substrate for the Yersinia protein kinase using chemical genetics and mass spectrometry. FEBS Lett 2006; 580: 179-83.
80. Barz C, Abahji TN, Trulzsch K, Heesemann J. The YersiniaSer/Thr protein kinase YpkA/YopO directly interacts with the small GTPases RhoA and Rac-1. FEBS Lett 2000; 482: 139-43.
81. Basseres E, Coppotelli G, Pfirrmann T, et al. The ubiquitin C-terminal hydrolase UCH-L1 promotes bacterial invasion by altering the dynamics of the actin cytoskeleton. Cell Microbiol 2010; 12: 1622-33.
82. Coombs N, Sompallae R, Olbermann P, et al. Helicobacter pyloriaffects the cellular deubiquitinase USP7 and ubiquitin-regulated components TRAF6 and the tumour suppressor p53. Int J Med Microbiol 2010.
83. Akimana C, Al-Khodor S, Abu Kwaik Y. Host factors required formodulation of phagosome biogenesis and proliferation of Francisella tularensis within the cytosol. Plos One 2010; 5: e11025.
84. Brummelkamp TR, Nijman SMB, Dirac AMG, Bernards R. Lossof the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappa B. Nature 2003; 424: 797-801.
85. Lim JH, Jono H, Koga T, et al. Tumor suppressor CYLD acts as anegative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One 2007; 2: e1032.
86. Sakai A, Koga T, Lim JH, et al. The bacterium, nontypeableHaemophilus influenzae, enhances host antiviral response by inducing Toll-like receptor 7 expression: evidence for negativeregulation of host anti-viral response by CYLD. FEBS J 2007; 274: 3655-68.
87. Lim JH, Ha UH, Woo CH, Xu H, Li JD. CYLD is a crucialnegative regulator of innate immune response in Escherichia coli pneumonia. Cell Microbiol 2008; 10: 2247-56.
88. Lim JH, Stirling B, Derry J, et al. Tumor suppressor CYLDregulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007; 27: 349-60.
89. Bomberger JM, Ye S, Maceachran DP, et al. A Pseudomonasaeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog 2011; 7: e1001325.
90. Bomberger JM, Barnaby RL, Stanton BA. The deubiquitinatingenzyme USP10 regulates the post-endocytic sorting of cystic fibrosis transmembrane conductance regulator in airway epithelial cells. J Biol Chem 2009; 284: 18778-89.
91. Rytkonen A, Poh J, Garmendia J, et al. SseL, a Salmonelladeubiquitinase required for macrophage killing and virulence. Proc Natl Acad Sci U S A 2007; 104: 3502-7.
92. Guiney DG, Fierer J. The Role of the spv Genes in SalmonellaPathogenesis. Front Microbiol 2011; 2: 129.
93. Mesquita FS, Thomas M, Sachse M, et al. The SalmonellaDeubiquitinase SseL Inhibits Selective Autophagy of Cytosolic Aggregates. PLoS Pathog 2012; 8: e1002743.
94. Ye Z, Petrof EO, Boone D, Claud EC, Sun J. Salmonella effectorAvrA regulation of colonic epithelial cell inflammation by deubiquitination. Am J Pathol 2007; 171: 882-92.
95. Liao AP, Petrof EO, Kuppireddi S, et al. Salmonella type IIIeffector AvrA stabilizes cell tight junctions to inhibit inflammation in intestinal epithelial cells. Plos One 2008; 3: e2369.
96. Mukherjee S, Keitany G, Li Y, et al. Yersinia YopJ acetylates andinhibits kinase activation by blocking phosphorylation. Science 2006; 312: 1211-4.
97. Jones RM, Wu H, Wentworth C, et al. Salmonella AvrACoordinates Suppression of Host Immune and Apoptotic Defenses via JNK Pathway Blockade. Cell Host Microbe 2008; 3: 233-44.
98. Sweet CR, Conlon J, Golenbock DT, Goguen J, Silverman N. Yop J. Targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction. Cell Microbiol 2007; 9: 2700-15.
99. Zhou H, Monack DM, Kayagaki N, et al. Yersinia virulence factorYopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J Exp Med 2005; 202: 1327-32.
100. Orth K, Xu Z, Mudgett MB, et al. Disruption of signaling byYersinia effector YopJ, a ubiquitin-like protein protease. Science 2000; 290: 1594-7.
101. Paquette N, Conlon J, Sweet C, et al. Serine/threonine acetylationof TGFbeta-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proc Natl Acad Sci U S A 2012; 109: 12710-5.
102. Catic A, Misaghi S, Korbel GA, Ploegh HL. Ela D. A Deubiqui-tinating Protease Expressed by E. coli. Plos One 2007; 2
103. Misaghi S, Balsara ZR, Catic A, et al. Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Mol Microbiol 2006; 61: 142-50.
104. Le Negrate G, Krieg A, Faustin B, et al. ChlaDub1 of Chlamydiatrachomatis suppresses NF-kappaB activation and inhibits IkappaBalpha ubiquitination and degradation. Cell Microbiol 2008; 10: 1879-92.
105. Tan KS, Chen Y, Lim YC, et al. Suppression of host innateimmune response by Burkholderia pseudomallei through the virulence factor TssM. J Immunol 2010; 184: 5160-71.
106. Shanks J, Burtnick MN, Brett PJ, et al. Burkholderia mallei tssMencodes a putative deubiquitinase that is secreted and expressed inside infected RAW 264.7 murine macrophages. Infect Immun 2009; 77: 1636-48.
107. Pearce MJ, Mintseris J, Ferreyra J, Gygi SP, Darwin KH. Ubiquitin-like protein involved in the proteasome pathway of Mycobacterium tuberculosis. Science 2008; 322: 1104-7.
108. Burns KE, Darwin KH. Pupylation vs. Ubiquitylation: Tagging forProteasome-Dependent Degradation. Cell Microbiol 2010.
109. Imkamp F, Striebel F, Sutter M, et al. Dop functions as adepupylase in the prokaryotic ubiquitin-like modification pathway. EMBO Rep 2010; 11: 791-7.
110. Imkamp F, Rosenberger T, Striebel F, et al. Deletion of dop inMycobacterium smegmatis abolishes pupylation of protein substrates in vivo. Mol Microbiol 2010; 75: 744-54.
111. Srivastav S, Kar S, Chande AG, Mukhopadhyaya R, Das PK. Leishmania donovani Exploits Host Deubiquitinating Enzyme A20, a Negative Regulator of TLR Signaling, To Subvert Host Immune Response. J Immunol 2012; 189: 924-34.
112. White RR, Miyata S, Papa E, et al. Characterisation of theTrichinella spiralis deubiquitinating enzyme, TsUCH37, an evolutionarily conserved proteasome interaction partner. PLoS Negl Trop Dis 2011; 5: e1340.
113. Frickel EM, Quesada V, Muething L, et al. Apicomplexan UCHL3retains dual specificity for ubiquitin and Nedd8 throughout evolution. Cell Microbiol 2007; 9: 1601-10.
114. Ponts N, Yang J, Chung DW, et al. Deciphering the ubiquitin-mediated pathway in apicomplexan parasites: a potential strategy to interfere with parasite virulence. Plos One 2008; 3: e2386.
115. Artavanis-Tsakonas K, Weihofen WA, Antos JM, et al. Characterization and structural studies of the Plasmodium falciparum ubiquitin and Nedd8 hydrolase UCHL3. J Biol Chem 2010; 285: 6857-66.
116. Artavanis-Tsakonas K, Misaghi S, Comeaux CA, et al. Identification by functional proteomics of a deubiquitinating/deNeddylating enzyme in Plasmodium falciparum. Mol Microbiol 2006; 61: 1187-95.
117. Hunt P, Afonso A, Creasey A, et al. Gene encoding adeubiquitinating enzyme is mutated in artesunate and chloroquine resistant rodent malaria parasites. Mol Microbiol 2007; 65: 27-40.
118. Ponder EL, Albrow VE, Leader BA, et al. Functionalcharacterization of a SUMO deconjugating protease of Plasmodium falciparum using newly identified small molecule inhibitors. Chem Biol 2011; 18: 711-21.
119. Fang W, Price MS, Toffaletti DL, et al. Pleiotropic Effects ofDeubiquitinating Enzyme Ubp5 on Growth and Pathogenesis of Cryptococcus neoformans. Plos One 2012; 7: e38326.
120. Blade J, Cibeira MT, Rosinol L. Bortezomib: a valuable newantineoplastic strategy in multiple myeloma. Acta Oncol 2005; 44: 440-8.
121. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib asthe First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives. Curr Cancer Drug Targets 2011.
122. Curran MP, McKeage K. Bortezomib: a review of its use inpatients with multiple myeloma. Drugs 2009; 69: 859-88.
123. Ooi MG, Hayden PJ, Kotoula V, et al. Interactions of theHdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009; 15: 7153-60.
124. Pham LV, Tamayo AT, Li C, et al. Degrasyn potentiates theantitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 2010; 9: 2026-36.
125. Perry JW, Ahmed M, Chang KO, et al. Antiviral Activity of aSmall Molecule Deubiquitinase Inhibitor Occurs via Induction of the Unfolded Protein Response. PLoS Pathog 2012; 8: e1002783.
126. Burkholder KM, Perry JW, Wobus CE, et al. A small moleculedeubiquitinase inhibitor increases localization of inducible nitric oxide synthase to the macrophage phagosome and enhances bacterial killing. Infect Immun 2011; 79: 4850-7.
127. Bartholomeusz GA, Talpaz M, Kapuria V, et al. Activation of anovel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007; 109: 3470-8.
128. Kapuria V, Peterson LF, Fang D, et al. Deubiquitinase inhibitionby small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010; 70: 9265-76.
129. Liu Y, Lashuel HA, Choi S, et al. Discovery of inhibitors thatelucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 2003; 10: 837-46.
130. Ratia K, Pegan S, Takayama J, et al. A noncovalent class ofpapain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A 2008; 105: 16119-24.
131. Chen X, Chou CY, Chang GG. Thiopurine analogue inhibitors ofsevere acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir Chem Chemother 2009; 19: 151-6.
132. Altun M, Kramer HB, Willems LI, et al. Activity-based chemicalproteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol 2011; 18: 1401-12.
133. Reverdy C, Conrath S, Lopez R, et al. Discovery of specificinhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol 2012; 19: 467-77.
134. Menard R, Sulea T. Selective inhibition of USP7. Chem Biol 2012;19: 437-8.
135. Tian X, Sh Isamiddinova N, Peroutka RJ, et al. Characterization ofSelective Ubiquitin and Ubiquitin-Like Protease Inhibitors Using a Fluorescence-Based Multiplex Assay Format. Assay Drug Dev Technol 2010; Dec 6.
136. Colland F, Formstecher E, Jacq X, et al. Small-molecule inhibitorof USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8: 2286-95.
137. Koterski JF, Nahvi M, Venkatesan MM, Haimovich B. VirulentShigella flexneri causes damage to mitochondria and triggers necrosis in infected human monocyte-derived macrophages. Infect Immun 2005; 73: 504-13.
138. Wessel D, Flugge UI. A method for the quantitative recovery ofprotein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984; 138: 141-3.
139. Edelmann MJ, Iphofer A, Akutsu M, et al. Structural basis andspecificity of human otubain 1-mediated deubiquitination. Biochem J 2009; 418: 379-90.
140. Peddinti D, Nanduri B, Kaya A, et al. Comprehensive proteomicanalysis of bovine spermatozoa of varying fertility rates and identification of biomarkers associated with fertility. BMC Syst Biol 2008; 2: 19.